Evidence map›Paper›PMID 38852478›Full record

ArticlePsychiatry research2024

Transcranial magnetic stimulation for methamphetamine use disorder: A scoping review within the neurocircuitry model of addiction.

J Ballester, W R Marchand, N S Philip

Registry-linked trialAbstract readScoping Review
In one paragraph

Article in Psychiatry research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06830980 (TMS), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06830980 nacompletednot on this mapstarted 2025, after this paper: background citation

TMS (Transcranial Magnetic Stimulation) for Methamphetamine Use Disorder in People Living With HIV

TypeinterventionalSponsorGopalkumar RakeshRan2025 to 2026Enrolled12ConditionsMethamphetamine Use Disorders, HIVArmsintermittent theta burst stimulation (iTBS), continuous theta burst stimulation (cTBS), Sham TMS
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

J BallesterSubstance Abuse Residential Rehabilitation Treatment Program, VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148, USA; Department of Psychiatry, School of Medicine, University of Utah, 501 Chipeta Way, Salt Lake City, UT 84108, USA. Electronic address: javier.ballester@hsc.utah.edu.
W R MarchandDepartment of Psychiatry, School of Medicine, University of Utah, 501 Chipeta Way, Salt Lake City, UT 84108, USA; VISN-19 Whole Health Flagship Site, VA Salt Lake City Health Care System, 500 Foothill Drive, Salt Lake City, UT 84148, USA; Animal, Dairy and Veterinary Sciences, Utah State University, 4815 Old Main Hill, Logan, UT 84322, USA.
N S PhilipDepartment of Psychiatry and Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA; VA RR&D Center for Neurorestoration and Neurotechnology, VA Providence Healthcare System, Providence, RI, USA.

Funding

Neuroimaging and Neuromodulation CoreP20GM130452 · NIGMS · BUTLER HOSPITAL (PROVIDENCE, RI) · PI GREENBERG, BENJAMIN D · 2019 to 2023
$11.3M
VA RR&D Center for Neurorestoration and NeurotechnologyI50RX002864 · VA · PROVIDENCE VA MEDICAL CENTER · PI BENJAMIN D GREENBERG, LEIGH R HOCHBERG · 2018 to 2026
–
NIGMS NIH HHS P20 GM130452RRD VA I50 RX002864
6 · The paper itself

Abstract

The use of methamphetamine in the United States is increasing, contributing now to the "fourth wave" in the national opioid epidemic crisis. People who suffer from methamphetamine use disorder (MUD) have a higher risk of death. No pharmacological interventions are approved by the FDA and psychosocial interventions are only moderately effective. Transcranial Magnetic Stimulation (TMS) is a relatively novel FDA-cleared intervention for the treatment of Major Depressive Disorder (MDD) and other neuropsychiatric conditions. Several lines of research suggest that TMS could be useful for the treatment of addictive disorders, including MUD. We will review those published clinical trials that show potential effects on craving reduction of TMS when applied over the dorsolateral prefrontal cortex (DLPFC) also highlighting some limitations that affect their generalizability and applicability. We propose the use of the Koob and Volkow's neurocircuitry model of addiction as a frame to explain the brain effects of TMS in patients with MUD. We will finally discuss new venues that could lead to a more individualized and effective treatment of this complex disorder including the use of neuroimaging, the exploration of different areas of the brain such as the frontopolar cortex or the salience network and the use of biomarkers.

Indexed as

Amphetamine-Related DisordersMethamphetamineTranscranial Magnetic StimulationBehavior, AddictiveCravingDorsolateral Prefrontal CortexHumansMethamphetamineAddictionBiomarkersCravingMethamphetamineNeuromodulationTranscranial magnetic stimulation

Identifiers

PMID38852478
PMCPMC11209858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.